Boston Scientific’s Obsidio Embolic Posts Clean 30-Day Results in Company-Sponsored Registry
A Boston Scientific-sponsored registry of 125 patients at 19 U.S. hospitals reports complete target-vessel occlusion and no rebleeding at 30 days with the Obsidio embolic. The single-arm design, company sponsorship and short follow-up limit what the results can show about the device.
Synchron Pauses Trials of Its Next-Generation Stentrode Over a Lead Problem, Says Safety Is Not the Issue
Synchron has paused trials of its second-generation brain-computer interface after reported problems with the lead connecting its vessel-based electrodes to the implant electronics. The company says safety is not the issue. It is cutting New York jobs and plans to bring lead design and manufacturing in-house.
FDA Clears Insera’s CLEAR Aspiration System, Which Pulses Suction to Remove Peripheral Clots
Insera Therapeutics has FDA 510(k) clearance for a thrombectomy system that pulses suction instead of holding it steady. The clearance covers peripheral arteries and veins and rests on bench and animal testing. No clinical outcome data were submitted, and no US launch date has been announced.
FDA Approves First Pediatric Heart Valve Designed to Be Expanded as Children Grow
The FDA has approved the Autus Size-Adjustable Valve, the first heart valve designed to be widened by balloon catheter as a child grows. Here is what the 62-patient study showed, and what is still unknown.